Credentialing the AI Doctor: The FDA's Blueprint for Generative AI

The FDA is asking the healthcare industry how to regulate generative AI medical devices. We unpack their proposed competency-based approach, which evaluates AI less like software and more like a human medical resident.

Key points

• Generative AI requires new regulatory frameworks because it produces variable outputs to similar inputs and can evolve after deployment.
• The FDA proposes a two-axis framework to assess risk based on device activity (how independently it acts) and the consequences of an incorrect output.
• A new competency-based premarket evaluation would mirror human clinician credentialing, using robust benchmarking and clinical confirmation.
• Postmarket monitoring could involve periodic re-benchmarking and shared responsibility across the healthcare ecosystem to catch performance degradation.
• The FDA suggests voluntary master files for foundation models, allowing developers to share underlying safety data without making it public.

Source: Considerations for the Regulation of Generative AI-Enabled Medical Devices: Discussion Paper and Request for Feedback - U.S. Food and Drug Administration, 2026

This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/credentialing-the-ai-doctor-the-fda-s-blueprint-for-generative-ai-944c85